SuperworthChampions Oncology EPS CSBR
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Apr 30, 2026
- −$0.08
- Latest quarter, Q4 FY26
- −$0.05
- Fiscal year 2026
- −$0.08
- −125% on the year before
Champions Oncology's earnings per share was −$0.08 over the twelve months to Apr 30, 2026, down 125% on a year earlier.
In its latest quarter, Q4 FY26, it was −$0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$0.08 | −125% |
| FY2025 | $0.32 | n/a |
| FY2024 | −$0.54 | n/a |
| FY2023 | −$0.39 | −1400% |
| FY2022 | $0.03 | +0% |
| FY2021 | $0.03 | n/a |
| FY2020 | −$0.17 | −1800% |
| FY2019 | $0.01 | n/a |
| FY2018 | −$0.14 | n/a |
| FY2017 | −$0.64 | n/a |
| FY2016 | −$1.20 | n/a |
| FY2015 | −$2.41 | n/a |
| FY2014 | −$1.32 | n/a |
| FY2013 | −$1.44 | n/a |
| FY2012 | −$2.28 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY26 | −$0.05 | n/a | −$0.08 | |
| Q3 FY26 | −$0.02 | −106% | −$0.16 | |
| Q2 FY26 | $0.02 | −60% | $0.17 | |
| Q1 FY26 | −$0.03 | −133% | $0.20 | |
| Q4 FY25 | −$0.13 | n/a | $0.32 | |
| Q3 FY25 | $0.31 | n/a | $0.44 | |
| Q2 FY25 | $0.05 | n/a | −$0.06 | |
| Q1 FY25 | $0.09 | n/a | −$0.26 | |
| Q4 FY24 | −$0.01 | n/a | −$0.54 | |
| Q3 FY24 | −$0.19 | n/a | −$0.72 | |
| Q2 FY24 | −$0.15 | n/a | −$0.71 | |
| Q1 FY24 | −$0.19 | n/a | −$0.56 |
Against its peers
Companies in Healthcare nearest Champions Oncology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CSBRChampions Oncology | n/m | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| NEPHNephros | $0.16 | +33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Champions Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.